Radium-223 treatment in mCRPC patient with Polycythemia Vera

. 2021; 30(3): 193-196

Radium-223 treatment in mCRPC patient with Polycythemia Vera

Cristina De Angelis¹, Viviana Frantellizzi¹, Mariano Pontico², Maria Silvia De Feo¹, Julia Lazri¹, Giuseppe De Vincentis¹
¹Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy
²Ph.d. Program In Morphogenesis & Tissue Engineering, Department Of Medico-surgical Sciences And Biotechnologies, Sapienza University Of Rome, Rome, Italy

Several studies have been provided concerning the clinical outcomes of Radium-223 treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). These patients may have an increased risk of hematologic comorbidities. To our knowledge, no data has yet been provided in literature about the potential bone marrow adverse effects of administering Radium-223 given in association with specific drugs used for hematologic conditions, such as polycythemia vera (PV).
We report the case of a mCRPC patient who received simultaneously Radium-223 treatment and hydroxyurea for PV, aiming to support clinicians to predict eventual adverse effects in these kinds of patients.

Keywords: Prostate cancer, mCRPC, Radium-223, Polycythemia Vera, hematogical toxicity

Cristina De Angelis, Viviana Frantellizzi, Mariano Pontico, Maria Silvia De Feo, Julia Lazri, Giuseppe De Vincentis. Radium-223 treatment in mCRPC patient with Polycythemia Vera. . 2021; 30(3): 193-196

Corresponding Author: Mariano Pontico, Italy

TOOLS

Download citation

RIS

EndNote

BibTex

Medlars

Procite

Reference Manager

Share with email

Send email to author

Similar articles

Google Scholar